In Vivo Distribution of 131I and 125I Dual-Labeled Gelatin Microspheres After Implantation into Rabbit Liver

Ma, Yu; Li, Bo; Li, Lin; Duan, Ligeng; Wei, Yonggang; Chen, Xiaoli

doi:10.1089/cbr.2011.1156

Cited by 8 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 35 days after injection, there were still large number of microspheres within the tumors (Figure 5D). In our previous studies, the microspheres which were injected into the parenchyma of liver of rabbits could still be observed by histological method even 32 days( 4 half-lives) after injection [27,28]. Perhaps much more effort is needed to retard the degradation of the microspheres, thus minimizing the de-labeling of radioiodine.…”

Section: Discussionmentioning

confidence: 99%

“…Gelatin microspheres are a type of derivative of collagen with a good level of biocompatibility, and they can be labeled with a high concentration of radioiodine. In our previous studies, we injected 131 I labeled gelatin microspheres and 131 I, 125 I dual-labeled gelatin microspheres into the liver parenchyma of rabbits, and we found that the injected microspheres mainly accumulated around the injection site, and the small amount of de-labeled radioiodine did not cause severe damage to other tissues [27,28]. In the present study, we evaluated use of 131 I-GMSs as an effective radiopharmaceutical for the treatment of transplanted human breast cancer (MCF-7) in nude mice following intratumoral injections.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

Chi

et al. 2014

Radiat Oncol

Self Cite

View full text Add to dashboard Cite

IntroductionThe aim of this study was to investigate the effects of 131I gelatin microspheres (131I-GMS) on human breast cancer cells (MCF-7) in nude mice and the biodistribution of 131I-GMSs following intratumoral injections.MethodsA total of 20 tumor-bearing mice were divided into a treatment group and control group and received intratumoral injections of 2.5 mci 131I-GMSs and nonradioactive GMSs, respectively. Tumor size was measured once per week. Another 16 mice received intratumoral injections of 0.4 mci 131I-GMSs and were subjected to single photon emission computed tomography (SPECT) scans and tissue radioactivity concentration measurements on day 1, 4, 8 and 16 postinjection. The 20 tumor-bearing mice received intratumoral injections of 0.4 mci [131I] sodium iodide solution and were subjected to SPECT scans and intratumoral radioactivity measurements at 1, 6, 24, 48 and 72 h postinjection. The tumors were collected for histological examination.ResultsThe average tumor volume in the 131I-GMSs group on post-treatment day 21 decreased to 86.82 ± 63.6%, while it increased to 893.37 ± 158.12% in the control group (P < 0.01 vs. the 131I-GMSs group). 131I-GMSs provided much higher intratumoral retention of radioactivity, resulting in 19.93 ± 5.24% of the injected radioactivity after 16 days, whereas the control group retained only 1.83 ± 0.46% of the injected radioactivity within the tumors at 1 h postinjection.Conclusions131I-GMSs suppressed the growth of MCF-7 in nude mice and provided sustained intratumoral radioactivity retention. The results suggest the potential of 131I-GMSs for clinical applications in radiotherapy for breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

Chi

et al. 2014

Radiat Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, glass-based radioactive microspheres are prone to reflux, poor distribution, and ectopic embolism, which will increase the incidence of radioactivity damage to nontarget tissues . Therefore, biodegradable polymers, such as albumin, gelatin, chitosan, and polylactic acid have been widely applied to develop radioactive microspheres. − Especially, biomass-derived radioactive microspheres take advantage of abundant resources, good biocompatibility, and renewable and environmentally friendly properties, which are beneficial for utilization in HCC treatment. However, the low radionuclide labeling rate, poor labeling stability, and the residual chemical reagents in the preparation of radioactive microspheres are still the crucial challenges related to the development of biodegradable radioactive microspheres .…”

Section: Introductionmentioning

confidence: 99%

¹³¹I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma

Shen

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Transarterial radioembolization (TARE) is a promising technology in hepatocellular carcinoma (HCC) therapy, which utilizes radionuclide-labeled microspheres to achieve arterial embolization and internal irradiation. However, the therapeutic effect of liver cancer can be affected by low radionuclide labeling rate and stability, as well as poor biocompatibility, and nonbiodegradability of microspheres. Here, 131 I-labeled silk fibroin microspheres ( 131 I-SFMs) were developed as radioembolization material for effective TARE therapy against HCC. Silk fibroin rich in 10.03% of tyrosine was extracted from silkworm cocoons and then emulsified and genipin-crosslinked to prepare SFMs. SFMs show a good settlement rate, biodegradability, hemocompatibility, and low cytotoxicity. Afterward, 131 I-SFMs were obtained by radiolabeling 131 I onto the SFMs through the chloramine-T method. 131 I-SFMs possess a high 131 I labeling rate of over 84% and good radioactive stability and are thus conducive to internal radiotherapy. Significantly, 131 I-SFMs with diameters around 11 μm were successfully radioembolized at the hepatic artery. 131 I-SFMs were diffused in the liver, indicating the favorable biodistribution and biosafety in vivo. Based on the combination of embolization and local radiotherapy, the administration of 131 I-SFMs shows a favorable inhibitive effect against the progression of HCC. Overall, the newly developed 131 I-SFMs as radioembolization microspheres provide a promising application for effective TARE therapy against liver cancer.

show abstract

“…Therefore, the 131 iodine in GM eluted more slowly and have a longer stagnation time in liver tumors than 131 iodine metuximab injection, which is likely to achieve better radiotherapy results. After demonstrating safety in animal experiments (18), we carried out a preliminary trial of TACE with 131 iodine-doxorubicineluting gelatin microspheres ( 131 I-DEM) in 11 patients with unresectable HCC. We present the following article in accordance with the STROBE reporting checklist (available at http://dx.doi.org/10.21037/jgo-21-105).…”

Section: Introductionmentioning

confidence: 99%

131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment

Ma¹,

Duan²,

Li³

et al. 2021

J Gastrointest Oncol

Self Cite

View full text Add to dashboard Cite

Background: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) with 131 iodine-doxorubicin-eluting gelatin microspheres ( 131 I-DEM TACE) compared with conventional TACE (cTACE) with polyvinyl alcohol foam (PVA) embolization microspheres. Methods: A total of 22 patients diagnosed with hepatocellular carcinoma were equally divided into 2 groups. The patients who underwent TACE with 131 I-DEM (25.7×10 7 Bq of 131iodine and 10 mg of doxorubicin) were compared to controls who received cTACE with PVA embolization microspheres. Therapeutic effects were evaluated by the tumor regression rates, levels of alpha-fetoprotein in serum, survival rates, and complications. Results: The operative complications of the 2 groups were not significantly different (P=0.753). The radioactivity ratio of the tumor to the liver was approximately 4.1:1 for the 131 I-DEM TACE group. In the 131 I-DEM TACE group, 54.5% of patients achieved tumor regression of more than 50%, compared to 36.6% of patients in the cTACE group. AFP levels in serum declined in 100% of patients in the 131 I-DEM TACE group and 50% of patients in the cTACE group. The median survival time of the patients was 12.0±3.3 months for the 131 I-DEM TACE group and 10.0±3.3 months for the cTACE group. There were no significant differences in survival between the 2 groups (P=0.414). Conclusions: 131I-DEM may become a potential radiochemoembolization agent to treat patients with unresectable hepatocellular carcinoma through TACE.

show abstract

In Vivo Distribution of ¹³¹I and ¹²⁵I Dual-Labeled Gelatin Microspheres After Implantation into Rabbit Liver

Abstract: (131)I-(125)I-GMS can be retained long term in the injection site. Due to the advantages of combining two radionuclides, (131)I-(125)I-GMS may be a safe and effective choice for cancer brachytherapy.

Cited by 8 publications

References 24 publications

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

¹³¹I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma

131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment

Contact Info

Product

Resources

About

In Vivo Distribution of 131I and 125I Dual-Labeled Gelatin Microspheres After Implantation into Rabbit Liver

Abstract: (131)I-(125)I-GMS can be retained long term in the injection site. Due to the advantages of combining two radionuclides, (131)I-(125)I-GMS may be a safe and effective choice for cancer brachytherapy.

Cited by 8 publications

References 24 publications

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma

131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment

Contact Info

Product

Resources

About

In Vivo Distribution of ¹³¹I and ¹²⁵I Dual-Labeled Gelatin Microspheres After Implantation into Rabbit Liver

¹³¹I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma